133 assets in Sickle Cell Disease

Therapeutic assets addressing Sickle Cell Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
itu512 Sickle Cell Disease	Novartis Pharmaceuticals	P1/2	CC (41)
Nula-Cel Sickle Cell Disease	Kamau Therapeutics	P1/2	CC (41)
Ruxolitinib Sickle Cell Disease	Arkansas Children's Hospital Research Institute	P1/2	CC (41)
Flurbiprofen Sickle Cell Disease	Pfizer	P1	CC (40)
Furosemide Sickle Cell Disease	Pfizer	P1	CC (40)
Motixafortide Sickle Cell Disease	St. Jude Children's Research Hospital	P1	CC (40)
Moxifloxacin Sickle Cell Disease	Novo Nordisk A/S	P1	CC (40)
Natalizumab Sickle Cell Disease	Washington University School of Medicine	P1	CC (40)
Omeprazole Sickle Cell Disease	Pfizer	P1	CC (40)
Repaglinide Sickle Cell Disease	Pfizer	P1	CC (40)
Rosuvastatin Sickle Cell Disease	Pfizer	P1	CC (40)
Autologous Bone Marrow Derived Cd34+ Hspcs Electroporated With Bcl11A Enhancer Targeting Cas9 Ribonucleoprotein Sickle Cell Disease	Daniel Bauer	P1	C (37)
Disc-3405 Sickle Cell Disease	Disc Medicine, Inc	P1	C (37)
Fostamatinib Sickle Cell Disease	National Heart, Lung, and Blood Institute (NHLBI)	P1	C (37)
Gene-Modified Cd34+ Cells Sickle Cell Disease	St. Jude Children's Research Hospital	P1	C (37)
LLP2A-CB-TE1A1P CU-64 Sickle Cell Disease	Enrico Novelli	P1	C (37)
Minocycline Sickle Cell Disease	University of Cincinnati	P1	C (37)
Multiple Vitamins Injection Sickle Cell Disease	EpiDestiny, Inc.	P1	C (37)
otq923 Sickle Cell Disease	Novartis Pharmaceuticals	P1	C (37)
Panobinostat Sickle Cell Disease	Abdullah Kutlar	P1	C (37)
Mgta-145 Sickle Cell Disease	Ensoma	P2	C (36)
Siplizumab Sickle Cell Disease	Columbia University	P1/2	C (36)
cs-206 Sickle Cell Disease	Children's Hospital of Fudan University	Early P1	C (34)
Brl-101 Sickle Cell Disease	Bioray Laboratories	N/A	D (28)
Carbon Dioxide Sickle Cell Disease	Washington University School of Medicine	N/A	D (28)
Immunoglobulin G4, Anti-(Human Lysyl Oxidase Homolog 2) (Human-Mus Musculus Monoclonal Gs-6624 Heavy Chain), Disulfide With Human-Mus Musculus Monoclonal Gs-6624 .Kappa.-Chain, Dimer Sickle Cell Disease	New York University	N/A	D (28)
Iohexol Sickle Cell Disease	University Hospital, Tours	N/A	D (28)
kl003 cell Sickle Cell Disease	Institute of Hematology & Blood Diseases Hospital, China	N/A	D (28)
T-Cell Surface Antigen T4/Leu-3 Sickle Cell Disease	City of Hope Medical Center	P1	D (28)
gsk4172239d Sickle Cell Disease	GlaxoSmithKline	P1	NR ()
Vas-101 Sickle Cell Disease	National Heart, Lung, and Blood Institute (NHLBI)	P1	NR ()

Showing 101 to 133 of 133 assets

PreviousPage 3 of 3Next